NDAORALTABLET
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Mechanism of Action
Janus Kinase Inhibitors
Pharmacologic Class:
Janus Kinase Inhibitor
Clinical Trials (5)
A Trial of Baricitinib in Patients With Cardiac Sarcoidosis
Started Apr 2026
10 enrolled
Cardiac Sarcoidosis
Baricitinib Curative Repression of HIV-1
Started Mar 2026
20 enrolled
HIV InfectionHIV
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Started Feb 2026
300 enrolled
Diabetes Mellitus, Type 1
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Started Jan 2026
150 enrolled
Diabetes Mellitus, Type 1
Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica
Started Dec 2025
140 enrolled
Polymyalgia Rheumatica (PMR)
Loss of Exclusivity
LOE Date
Nov 30, 2032
82 months away
Patent Expiry
Nov 30, 2032